TROV Share Price

Open 0.69 Change Price %
High 0.70 1 Day 0.00 0.00
Low 0.66 1 Week -0.04 -5.63
Close 0.67 1 Month -0.15 -18.29
Volume 456525 1 Year -4.05 -85.81
52 Week High 4.90
52 Week Low 0.61
TROV Important Levels
Resistance 2 0.71
Resistance 1 0.69
Pivot 0.68
Support 1 0.65
Support 2 0.63
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ASTI 0.00 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
ALNY 113.84 51.71%
LOCM 0.09 50.00%
VALV 0.03 50.00%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
ORIG 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

TrovaGene, Inc. (NASDAQ: TROV)

TROV Technical Analysis 5
As on 20th Sep 2017 TROV Share Price closed @ 0.67 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.63 & Strong Sell for SHORT-TERM with Stoploss of 0.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
TROV Target for September
1st Target up-side 0.8
2nd Target up-side 0.89
3rd Target up-side 0.99
1st Target down-side 0.52
2nd Target down-side 0.43
3rd Target down-side 0.33
TROV Other Details
Segment EQ
Market Capital 54819236.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.trovagene.com
TROV Address
TROV
11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States
Phone: 858-952-7570
TROV Latest News
Interactive Technical Analysis Chart TrovaGene, Inc. ( TROV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TrovaGene, Inc.
TROV Business Profile
TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).